Skip to content

Home Map The News Technology Politics Business Sports Entertainment

Global AI-Powered News Intelligence. Real-time headlines, mapped by continent and country, from authoritative sources worldwide.

Powered by AI

Navigate

Home
Map The News
About
Search

Sections

Technology
Politics
Business
Sports
Entertainment

More

Privacy
Contact
Sitemap
Robots

© 2026 newsGlobal. All rights reserved.

Headlines refresh every 10 minutes.

Home Map Search Topics About

Home / Business

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

Financial Times

BusinessFinancial Times·Jun 9, 2026·1 min read

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year

View original source — Financial Times ↗

ShareShare on X Share on Facebook

Related stories

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

BusinessJun 9, 2026 · 1 min

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

GSK Agrees to Buy Nuvalent for $10.6 Billion

BusinessJun 9, 2026 · 1 min

GSK Agrees to Buy Nuvalent for $10.6 Billion

GSK to buy US cancer treatment firm Nuvalent for $10.6bn

BusinessJun 9, 2026 · 1 min

GSK to buy US cancer treatment firm Nuvalent for $10.6bn

GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down

BusinessJun 9, 2026 · 1 min

GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down